Literature DB >> 15793157

Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations.

Heather K Sun1, Christine T Ong, Ambreen Umer, Dawn Harper, Steven Troy, Charles H Nightingale, David P Nicolau.   

Abstract

The pharmacokinetics of tigecycline, when given as a 100-mg loading dose followed by 50 mg every 12 h, were determined in serum and blister fluid. The peak tigecycline concentration and half-life in serum were greater than those in blister fluid. Tigecycline penetrates into blister fluid well, with a mean penetration rate of 74%.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15793157      PMCID： PMC1068611          DOI： 10.1128/AAC.49.4.1629-1632.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci.

Authors:  D B Hoellman; G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

2.  Pharmacokinetic profile of meropenem, administered at 500 milligrams every 8 hours, in plasma and cantharidin-induced skin blister fluid.

Authors:  Dana Maglio; Renli Teng; Per T Thyrum; Charles H Nightingale; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

3.  Production and resolution of cantharidin-induced inflammatory blisters.

Authors:  Dana Maglio; Charles H Nightingale; David P Nicolau
Journal:  Int J Antimicrob Agents       Date:  2003-07       Impact factor: 5.283

4.  Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates.

Authors:  D Milatovic; F-J Schmitz; J Verhoef; A C Fluit
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

5.  In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases.

Authors:  D J Biedenbach; M L Beach; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2001-08       Impact factor: 2.803

6.  In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain.

Authors:  Carmen Betriu; Iciar Rodríguez-Avial; Blas Ali Sánchez; María Gómez; Juan Alvarez; Juan J Picazo
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

7.  In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.

Authors:  Peter J Petersen; Patricia A Bradford; William J Weiss; Timothy M Murphy; P E Sum; Steven J Projan
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000).

Authors:  Robert P Rennie; Ronald N Jones; Alan H Mutnick
Journal:  Diagn Microbiol Infect Dis       Date:  2003-04       Impact factor: 2.803

9.  Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study.

Authors:  Daryl Hoban; Ken Waites; David Felmingham
Journal:  Diagn Microbiol Infect Dis       Date:  2003-04       Impact factor: 2.803

10.  Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy.

Authors:  Mark E Jones; James A Karlowsky; Deborah C Draghi; Clyde Thornsberry; Daniel F Sahm; Dilip Nathwani
Journal:  Int J Antimicrob Agents       Date:  2003-10       Impact factor: 5.283
View more
  17 in total

1.  Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.

Authors:  Catharine C Bulik; Dora E Wiskirchen; Ashley Shepard; Christina A Sutherland; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections.

Authors:  S A Van Wart; J S Owen; E A Ludwig; A K Meagher; J M Korth-Bradley; B B Cirincione
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

Review 3.  Tigecycline.

Authors:  James E Frampton; Monique P Curran
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Tissue penetration of telavancin after intravenous administration in healthy subjects.

Authors:  Heather K Sun; Kenneth Duchin; Charles H Nightingale; Jeng-Pyng Shaw; Julie Seroogy; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

5.  New drugs to treat skin and soft tissue infections.

Authors:  Gary E Stein
Journal:  Curr Infect Dis Rep       Date:  2007-09       Impact factor: 3.725

6.  [Septic shock due to vancomycin-resistant enterococci infection. Tigecycline monotherapy].

Authors:  S Swoboda; T Hoppe-Tichy; H K Geiss; C Hainer; T H Nguyen; H-P Knaebel; M A Weigand
Journal:  Anaesthesist       Date:  2007-02       Impact factor: 1.041

7.  In vitro activity of tigecycline against Burkholderia pseudomallei and Burkholderia thailandensis.

Authors:  Visanu Thamlikitkul; Suwanna Trakulsomboon
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

8.  In vitro activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci.

Authors:  Janet A Hindler; Annie Wong-Beringer; Carmen L Charlton; Shelley A Miller; Theodoros Kelesidis; Marissa Carvalho; George Sakoulas; Poochit Nonejuie; Joseph Pogliano; Victor Nizet; Romney Humphries
Journal:  Antimicrob Agents Chemother       Date:  2015-05-11       Impact factor: 5.191

9.  Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics.

Authors:  Nickie D Greer
Journal:  Proc (Bayl Univ Med Cent)       Date:  2006-04

10.  Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.

Authors:  Pornpan Koomanachai; Jared L Crandon; Mary Anne Banevicius; Li Peng; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.